Oct. 22 at 12:32 PM
$BCAB CLDN18.2 is overexpressed in gastric cancer (60–80%) and pancreatic cancer (50%), but GI toxicity in conventional ADCs is a problem due to limited expression in the normal gastrointestinal tract. CAB can address this issue.
Currently, CLDN18.2 ADC (e.g., IBI343, CMG901) reduces toxicity with glycan-based or Fc-silenced designs, but like CAB, environment-dependent activation is more innovative. Although BioAtla has not yet released CLDN18.2 CAB-ADC, it is technically compatible, and BioAtla's platform is being applied to various targets (AXL, ROR2).